Lamisil (Terbinafine Hydrochloride)

Terbinafine blocks the fungal enzyme squalene epoxidase, which is essential for producing ergosterol, a key component of fungal cell membranes. Inhibiting this step leads to a buildup of squalene and a deficiency of ergosterol, destabilizing the membrane and causing fungal cell death while sparing human cells.

The specific amount and frequency of Lamisil topical application are determined by the prescribing healthcare professional based on the infection type, severity, patient age and body surface area involved. Patients should follow the prescriber’s instructions and the product label carefully.

Safety data for topical terbinafine during pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using Lamisil.

To place an order, submit an enquiry on the Lamisil product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lamisil (terbinafine) belongs to the allylamine class, which often provides faster fungicidal activity compared with azole antifungals. It is particularly effective against dermatophytes and may require a shorter treatment duration, though choice of therapy depends on infection type, patient factors and clinician preference.

Lamisil should be stored at room temperature, ideally below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

The cream is applied to clean, dry skin in a thin layer over the affected area, usually once or twice daily as directed by a healthcare professional. The area should be gently massaged until the product is absorbed, and hands should be washed after application.

While rare, serious adverse reactions can include severe allergic responses such as anaphylaxis, Stevens‑Johnson syndrome, toxic epidermal necrolysis, and significant swelling or blistering of the treated skin. Any signs of a severe reaction require immediate medical attention.

Lamisil should not be used by individuals with a known hypersensitivity to terbinafine or any component of the formulation. It is also contraindicated on broken skin, mucous membranes, or in patients who have experienced severe cutaneous reactions to topical antifungals.